SCHEMBL2486035

SCHEMBL2486035

COC(=O)/C(O)=C/C(=O)c1oc(-c2ccc(C)cc2)cc1Cc1ccc(F)cc1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.38
RET P07949 1/20 0.38
MAPT P10636 1/20 0.38
KDR P35968 1/20 0.38
TP53 P04637 1/20 0.37
KDM4E B2RXH2 3/20 0.36
LMNA P02545 1/20 0.36
HPGD P15428 1/20 0.36
POLB P06746 1/20 0.36
ANO1 Q5XXA6 1/20 0.36
CNR1 P21554 4/20 0.36
CNR2 P34972 4/20 0.36
GPR55 Q9Y2T6 1/20 0.36
L3MBTL1 Q9Y468 1/20 0.35
GLA P06280 1/20 0.35
PDE4B Q07343 1/20 0.35
PDE4D Q08499 1/20 0.35
AKR1C4 P17516 1/20 0.35
AKR1C3 P42330 1/20 0.35
AKR1C2 P52895 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2486036 1.00 ALDH1A1 (0.38) ALDH1A1RETMAPTKDRTP53
SCHEMBL753146 0.85 CNR2 (0.37) ALDH1A1MAPTKDM4ELMNAHPGD
SCHEMBL753145 0.85 CNR2 (0.37) ALDH1A1MAPTKDM4ELMNAHPGD
SCHEMBL2485043 0.81 MAPK14 (0.42) ALDH1A1KDM4EHPGDCNR1CNR2
SCHEMBL2485045 0.81 MAPK14 (0.42) ALDH1A1KDM4EHPGDCNR1CNR2
SCHEMBL755491 0.80 RAB9A (0.34) ALDH1A1MAPTLMNAHPGDPOLB
SCHEMBL755492 0.80 RAB9A (0.34) ALDH1A1MAPTLMNAHPGDPOLB
SCHEMBL753978 0.79 RET (0.45) ALDH1A1RETMAPTKDRTP53
SCHEMBL754113 0.79 CA12 (0.34) ALDH1A1KDM4EHPGDPOLBCNR1
SCHEMBL754114 0.79 CA12 (0.34) ALDH1A1KDM4EHPGDPOLBCNR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20170066754-A1 ANTIVIRAL AGENT SHIONOGI & CO., LTD. (JP) 2017-03-09 US disclosed
US-9572813-B2 Antiviral agent SHIONOGI & CO., LTD. (JP) 2017-02-21 US disclosed
US-20150202208-A1 ANTIVIRAL AGENT SHIONOGI & CO., LTD. (JP) 2015-07-23 US disclosed
EP-2181985-B1 Antiviral Agent SHIONOGI & CO (JP) 2011-10-26 EP disclosed
EP-2266958-A1 Antiviral agent SHIONOGI & CO., LTD. (JP) 2010-12-29 EP disclosed
US-20040229909-A1 Antiviral agent SHIONOGI & CO., LTD. (JP) 2004-11-18 US disclosed
EP-1422218-A1 ANTIVIRAL AGENT SHIONOGI & CO., LTD. (JP) 2004-05-26 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040229909-A1 Antiviral agent ZC3HAV1, ZC3HAV1L, DUT ALDH1A1 658/4885RET 3941/4885MAPT 4635/4885
US-20150202208-A1 ANTIVIRAL AGENT ZC3HAV1, ZC3HAV1L, CCNI ALDH1A1 424/4885RET 3047/4885MAPT 4426/4885
US-20170066754-A1 ANTIVIRAL AGENT ZC3HAV1, ZC3HAV1L, CCNI ALDH1A1 424/4885RET 3047/4885MAPT 4426/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.